AUS
NZ
UK
CA
USA
IND
_06_16_2026_01_38_04_856127.jpg)
In the Dow Jones Index, Disney and Johnson & Johnson represent two different sectors—communication services and healthcare, respectively. Both companies have comparable revenue bases of around $85-$90 billion, but they exhibit distinct financial characteristics and performance trends. This article explores their relative performance and financial metrics, highlighting their positions as value stocks in their respective sectors.
Stock Performance Overview
Johnson & Johnson (NYSE:JNJ) has experienced a 20% increase in stock price from early January 2021, rising from $140 to approximately $165. In contrast, Disney’s stock has faced a significant decline of 50%, dropping from $180 to $90 over the same period. The broader S&P 500 index has seen a 45% rise during this time.
Johnson & Johnson's stock performance varied in Healthcare sector, with returns of 11% in 2021, 6% in 2022, and a 9% decline in 2023. Disney’s returns, on the other hand, were -15% in 2021, -44% in 2022, and a 4% gain in 2023. Both stocks have underperformed relative to the S&P 500 index, which recorded returns of 27% in 2021, a 19% decline in 2022, and a 24% gain in 2023.
Disney Outpaces Johnson & Johnson
In terms of revenue growth, Disney (NYSE:DIS) has demonstrated stronger performance compared to Johnson & Johnson. Disney’s revenue increased by 32%, from $67.4 billion in fiscal 2021 to $88.9 billion in fiscal 2023. Johnson & Johnson saw a more modest 8% revenue rise, from $78.7 billion in 2021 to $85.2 billion in 2023.
Disney’s revenue growth has been primarily driven by its theme park operations, which rebounded significantly following COVID-19 restrictions. Additionally, Disney's streaming services have contributed to revenue increases, despite slowing subscriber growth in recent quarters. For perspective, Disney+ core subscribers grew by only 1% sequentially in the third quarter of fiscal 2024, while Disney+ Hotstar subscribers decreased by 1%, and Hulu subscribers grew by 2%.
Johnson & Johnson's revenue growth has been supported by its pharmaceuticals and medical devices segments. Key drivers include the success of drugs like Darzalex and Stelara, although some older drugs face generic competition and declining sales. The company’s acquisition of Abiomed has strengthened its cardiovascular care segment.
Profitability and Margins
Johnson & Johnson has maintained a higher operating margin compared to Disney. J&J’s operating margin increased from 26.6% in 2021 to 27.5% in 2023. In contrast, Disney’s operating margin nearly doubled from 5.4% to 10.1% during the same period. Over the last twelve months, Johnson & Johnson’s operating margin stands at 27.6%, while Disney’s is at 12.5%. Disney faces challenges from rising costs and expected normalization in theme park attendance, which could affect its margin profile.
Financial Risk Assessment
When assessing financial risk, Johnson & Johnson exhibits a stronger position. J&J has a debt-to-equity ratio of 10%, significantly lower than Disney’s 29%. Additionally, J&J maintains a 14% cash reserve as a percentage of assets, compared to Disney’s 3%. This indicates that Johnson & Johnson has a more robust financial cushion and lower debt risk.
Disney has shown superior revenue growth compared to Johnson & Johnson, but J&J demonstrates higher profitability and lower financial risk. The current valuations suggest Disney’s stock might have more room for growth, whereas Johnson & Johnson’s stock appears to be priced appropriately. These metrics offer insight into the companies' financial health and market positioning.
